Löwenberg, Bob; Pabst, Thomas; Vellenga, Edo; van Putten, Wim; Schouten, Harry C; Graux, Carlos; Ferrant, Augustin; Sonneveld, Pieter; Biemond, Bart J; Gratwohl, Alois; de Greef, Georgine E; Verdonck, Leo F; Schaafsma, Martijn R; Gregor, Michael; Theobald, Matthias; Schanz, Urs; Maertens, Johan; Ossenkoppele, Gert J (2011). Cytarabine dose for acute myeloid leukemia. New England journal of medicine NEJM, 364(11), pp. 1027-36. Waltham, Mass.: Massachusetts Medical Society MMS
Full text not available from this repository.Cytarabine (ara-C) is an important drug in the treatment of acute myeloid leukemia (AML). High-dose cytarabine (2000 to 3000 mg per square meter of body-surface area) is toxic but results in higher rates of relapse-free survival than does the conventional dose of 100 to 400 mg per square meter. Intermediate dose levels have not been thoroughly evaluated.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Pabst, Thomas Niklaus |
ISSN: |
0028-4793 |
Publisher: |
Massachusetts Medical Society MMS |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:20 |
Last Modified: |
02 Mar 2023 23:20 |
PubMed ID: |
21410371 |
Web of Science ID: |
000288439000008 |
URI: |
https://boris.unibe.ch/id/eprint/6466 (FactScience: 211432) |
Actions (login required)
 |
Edit item |